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ABSTRACT 
Efficacy and safety of new antipsychotic agent-risperidone was evaluated in the confirmed 
schizophrenic patients of either sex, over 15 years of age. Of the 30 patients who entered the 
study, 27 completed the trial as per the protocol and only 3 dropped out, one was lost to follow up, 
the other was an uncooperative patient who pulled out of the trial due to moderate side effects 
while one patients withdrew the consent at his own free will. The significant improvements were 
seen in the broad range of symptoms of schizophrenia at various time points in the trial. The 
significant beneficial effect on negative symptoms was particularly obvious. The drug was well 
tolerated by most patients, and side effects, when reported, were mild. Even the extrapyramidal 
symptoms reported could be easily controlled with oral trihexyphenidyl hydrochloride. The ex-
haustive extrapyramidal symptom rating scale also did not show any worsening during risperidone 
therapy. The efficacy and safety profile of novel antipsychotic drug risperidone makes it a useful 
therapeutic agent in the broad range of patients with schizophrenia. 
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The well established effectiveness of 
currently available antipsychotic agent is off-
set by their limitations. These agents are not 
useful in all psychotic patients, and many a 
times they cause serious neurological side ef-
fects. At times, even the patients responding 
to them are left with serious disabilities. Such 
limitations have made psychiatrists to look for 
agents with better or at least similar efficacy 
and with lesser side effects causing potential. 
Risperidone is a novel antipsychotic 
agent which combines potent serotonin 5HT2 
and dopamine D2 receptor antagonism (Grant 
& Kitton, 1994). Advantages offered by risperi-
done over haloperidol include a faster onset of 
antipsychotic action, a lower incidence of ex-
trapyramidal effects and greater efficacy 
against the negative symptoms of schizophre-
nia. It is suggested that risperidone may also 
play a role in reducing hospital days for the 
chronic schizophrenic population (Addington e,t 
al., 1993). 
At our centre we have substantial number 
of patients who have a long standing history of 
schizophrenia and they are either not adequately 
controlled with the existing neuroleptics or de-
velop side effects with them. We decided to 
evaluate the broad spectrum antipsychotic 
agent-risperidone in our schizophrenic patients 
to assess its safety and efficacy. The effort was 
also made to evaluate the effect of risperidone 
on negative symptoms and to 
assess whether the beneficial effects were 
achievable without increasing the occurrence of 
side effects. 
MATERIAL & METHOD 
The open study with a treatment 
duration of 4 months was designed. 
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The frequecy and timings of various safety evalutions are represented in the following table 
Physical exam 
Lab.,ECG 
Vital signs 
VISIT 
DAY 
WEEKS 
.& weight 
PANSS & BPRS 
CGI 
ESRS 
Adv. Exp. 
Disp. Med. 
1 
0 
X 
X 
X 
X 
X 
X 
X 
2 
7 
X 
X 
X 
X 
3 
14 
X 
X 
X 
X 
4 
28 
X 
X 
X 
X 
X 
X 
5 
6 
X 
X 
X 
X 
6 
8 
X 
X 
X 
X 
7 
10 
X 
X 
X 
X 
X 
X 
8 
12 
X 
X 
X 
X 
9 
14 
X 
X 
X 
X 
10 
16 
X 
X 
x 
X 
X 
X 
X 
Patients inclusion criteria: Patients of either sex, 
over the age of 15 years and diagnosed as suf-
fering from schizophrenia or schizophreniform 
disorder (as per DSM-III-R criteria) were con-
sidered for the study. 
The patients with any of the following were ex-
cluded from the study : 
- Women in reproductive age group without 
adequate contraception. 
- Pregnancy and lactation. 
- Patients receiving a depot neuroleptic within 
one treatment cycle of the time of selection. 
- Patients receiving oral/parenteral neuroleptic 
within 3 days prior to the day of selection for 
study. 
-Patients with clinically relevant organic/neuro-
logic disease or abnormal laboratory tests, or 
with abnormal ECG findings. 
- Patients with a diagnosis of psychoactive sub-
stance abuse. 
- Patients who were included in trial with 
investigational drugs during the 4 weeks 
preceding this trial. 
During the first week of the trial, the 
patients were preferably hospitalised, if possi-
ble. Thereafter, they were treated on an in or 
out patient basis. 
Before entering the study an informed, 
written consent was obtained from each of the 
patient. 
Each patient received risperidone 1 mg 
twice a day on day one, 2 mg twice a day on 
day two, and 3 mg twice a day on day three. 
The dosage of 3 mg twice a day was continued 
till the end of first week. On 7th day, if the Clini-
cal Global Impression (CGI) was rated as 
"improved" then that patient's total daily dose 
(6 mg) remained unchanged. If on day 7, CGI 
was rated as "unchanged" or "worsened" then 
the total daily dose was increased to 8 mg (4 
mg twice a day). On day 14, the same previous 
daily dose was continued if CGI rating was 
improved. If the rating was "unchanged" or 
"worsened" the daily dose of risperidone was 
increased by 4 mg per week without exceeding 
the maximum daily dose of 16 mg. (2 tablets of 
4 mg. twice a day). From day 29 onwards for 
the next 3 months the dose of risperidone was 
kept unchanged as far as possible. However, 
dose adaptations were permissible if necessary. 
During the trial period, except for risperi-
done, no other antipsychotic was administered. 
All other concomitant medications received by 
the patients were recorded"1n detail. Any pa-
tient developing extrapyramidal symptoms was 
prescribed an anticholinergic, if necessary. 
Benzodiazepine was used, only when required, 
for additional sedation. 
Efficacy evaluation : 
Positive and Negative Syndrome Scale 
(PANSS) (Kay et al., 1992) for schizophrenia 
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and Brief Psychiatric Rating Scale (BPRS) were 
used. Overall efficacy was assessed using the 
Clinical Global Impression (CGI). The frequency 
and timings of these evaluations are represented 
in the following table. 
Safety evaluation 
To achieve this the following criteria were used. 
(a) Routine physical & neurological examina-
tion 
(b) Extrapyramidal Symptoms Rating Scale 
(ESRS) (Chouinard et al., 1980) 
(c) Vital signs 
(d) Laboratory tests 
-Haematology : hemoglobin, RBC count, 
WBC count (total & differential), platelet count. 
-Blood biochemistry sodium, potassium, 
chloride, total protein, glucose, total bi 
lirubin. alkaline phosphatase, GGT, AST, 
ALT, urea, creatinine, uric acid. 
-Urine analysis : protein, glucose, occult 
blood 
-ECG 
All the cases, throughout the trial were 
closely monitored for any adverse effects. When 
noted, adverse effects were recorded in detail. 
The authors used Wilcoxon matched-pairs 
TABLE 1 
PANSS, BPRS 4 CGI (MEAN SCORES) 
Positive 
Negative 
General 
Total PANSS 
BPRS 
CGI 
Basal 
(±SE) 
15.04 
(1.067) 
21 56 
(1.326) 
35.74 
(1 249) 
72.33 
(2837) 
38 96 
(1 897) 
3 52 
(0 135) 
Week 4 
(±S.E.) 
' 12.63"* 
(0.766) 
18 89" 
(1 079) 
31.67— 
(1 425) 
62.82*" 
(2 384) 
33 82*" 
(1 444) 
300" 
(0131) 
Week 10 
(tS.E.) 
11.11 — 
(0.902) 
16.70— 
(0929) 
28 44— 
(1 385) 
56.26— 
(2.576) 
30 44— 
(1 328) 
252*" 
(0 154) 
Week 16 
(±S.E.) 
10 78*" 
(0909) 
16.11— 
(1 162) 
27.44— 
(1.442) 
54 33*" 
(2.990) 
29.07— 
(1 377) 
226*" 
(0156) 
*p<0 05, **p<0 01. "* p<0.001 
TABLE 2 
EXTRAPYRAMIDAL SYMPTOMS RATING SCALE (ESRS 
ESRS 
Questionnaire 
total score 
Parkinsonism 
total score 
Dystonia total 
score 
Parkinsonism 
•Dystonia total 
score 
Dyskinesia 
total score 
Parkinsonism + 
dystonia* 
dyskinesia total 
score 
Basal 
(t S.E.) 
0.926 
(0.244) 
1.889 
(0.493) 
0.000 
(0.000) 
1889 
(0.493) 
0000 
(0.000) 
1.889 
(0.493) 
Clinical Global 0.222 
Impression (CGI)(0.154) 
of dyskinesia 
Clinical Global 0 830 
Impression (CGI) (0.178 
of parkinsonism 
Mean Scores 
Week 4 
(* S.E.) 
0.704 
(0.198) 
1.852 
(0.626) 
0.000 
(0.000) 
1.852 
(0.626) 
0.000 
(0.000) 
1.852 
(0.626) 
0.148 
(0.116) 
0.704 
(0.212) 
Week 10 Week 16 
(±S.E.) (tS.E.) 
0.667 
(0.220) 
2.074 
(0.823) 
0.037 
(0.037) 
2.111 
(0.824) 
0.000 
(0.000) 
2.111 
(0.824) 
0037 
(0.037) 
0.778 
(0.252) 
0.630 
(0.201) 
1.85 
(0.472) 
0.000 
(0.000) 
1.185 
(0.472) 
0.000 
(0.000) 
1.185 
(0.472) 
0.000 
(0.000) 
0667 
(0.192) 
signed-ranks test for the statistical analysis of 
efficacy and the safety results wherever 
applicable. 
RESULTS 
The study was conducted at Maharash-
tra Institute of Mental Health, Mental Health 
Promotion, Training and Research Organisa-
tion, Sassoon Hospital Campus, Pune, from 
February, 1996 to June, 1997. 
A total of 30 cases (28 males and 2 
females) were enrolled in the trial. The mean 
age of the patients was 30.9 years while 
median age was 28.5 years. The mean 
duration of schizophrenic disease in our patient 
population was 6.92 years (minimum 1 year/ 
maximum 25 years). The majority of the 
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TABLE 3 
ADVERSE EVENTS 
Tremor 
Rigidity 
Sialorrhoea 
Extrapyramidal symptoms 
Nausea and vomiting 
Headache 
Pain in abdomen 
Palpitation 
Oculogyric crisis 
Akathisia 
No. (%) of patients 
4(13.33) 
3 (10.0) 
3 (10.0) 
1(3.33) 
1(3.33) 
1(3.33) 
1(3.33) 
1(3.33) 
1(3.33) 
1 (3.33) 
patients (26 out of 30) were less than 45 years 
of age. 
Three of the patients dropped out of the 
study. One was lost to follow up, the other pa-
tient was uncooperative and complained of in-
sufficient response, and dropped out of the 
trial as he also had adverse effects (headache, 
pain in abdomen and palpitations). One patient 
withdrew the consent for the trial at his own free 
will. The remaining 27 patients completed the 
trial as per the protocol. The analysis has been 
carried out of the complete data available from 
27 patients, however, the side effects occur-
rence covers all the 30 patients. Statistical 
analysis indicated that there were no significant 
differences in the baseline readings (age, 
PANSS and sub scales, BPRS) between the 
patients completing the trials and .the ones that 
dropped out. 
There were consistent and highly signifi-
cant reductions in the mean scores attributed 
to the positive, negative and the general psy-
chopathological symptoms as well as total 
PANSS scores at all the time periods (4, 10 and 
16 weeks). The improvements were noted ear-
lier in many patients. Highly significant reduc-
tions were also noted in mean BPRS scores at 
4, 10 as well as 16 week (Table 1). Eighteen 
patients (66.7%) had reduction of 20% or more 
in their total PANSS scores at the end of 16 
weeks and hence were considered clinically 
improved. Seventeen patients (62.9%) showed 
similar reduction in their BPRS scores. 
Clinical Global Impression (CGI) mean 
scores also were significantly reduced at 4, 10 
and 16 weeks as compared to the baseline 
(Table 1). At 16 weeks eighteen patients (66.7%) 
were considered as not ill, or mildly so. Seven-
teen patients (63.0%) were considered as very 
much or much improved as compared to their 
condition at the start of the trial. 
The exhaustive Extrapyramidal Symptom 
Rating Scale (ESRS) mean scores revealed that 
there were no significant differences in any of 
the parameters studied (Table 2) as compared 
to the baseline status at all the time points in 
the study (4, 10 and 16 weeks). 
Adverse events reported have been listed 
in table 3. The one or more adverse events were 
reported by 12 (40%) patients, however, they 
were mild and did not necessitate the discon-
tinuation of therapy except in one case. The 
Extrapyramidal Symptoms (EPS), were mild, 
and treated with trihexyphenidyl hydrochloride 
tablets. 
One of the patients continued to complain 
of nausea and vomiting and hence the dose was 
reduced to 4 mg and maintained at that level 
throughout. The other patient when given 8 mg 
developed tremors, the reduction of risperidone 
dose to 4 mg a day and administration of 
trihexyphenidyl hydrochloride tablets completely 
controlled the adverse effects and he was then 
maintained at that dose. The mean daily dose 
of risperidone used was 8.96 mg in our patients 
who had a long standing history of schizophre-
nia. 
The mean weight showed a rise at the 
end (65.7 kg) of trial as compared to the 
pretherapy (63.9 kg) level. 
DISCUSSION 
Risperidone was significantly effective in 
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causing the improvements in most of the schizo-
phrenic patients enrolled in the study. Most of 
the patients tolerated the effective recom-
mended doses. The improvements were seen 
in positive as well as general psychopathologi-
cal symptoms, as indicated by the scores. The 
very impressive fact was that there were marked 
improvements in the negative symptoms as 
well. The improvements also tended to occur 
speedily. 
The ability of risperidone to continue to 
be effective and safe even on long term follow 
up was noted in early studies. Early open main-
tenance study had reported that schizophrenic 
patients who received risperidone 0.5-22.5 
mg/day, for 1 year showed at least 50% reduc-
tion in total BPRS scores in 62% of cases, and 
37% had at least 75% reduction in their scores 
(Mertens. 1991). 
Another important issue which needs to 
be addressed is the utility of risperidone in re-
fractory cases. In our study it was interesting to 
note that, the average duration of schizophrenic 
disease was 6.92 years and many of these pa-
tients were resistant to the previously adminis-
tered antipsychotic therapy, in spite of this fact 
over 66% of the patients were considered as 
responders to risperidone, with the reduction of 
at least 20% in their total PANSS scores. Over 
66% of patients were considered as not ill or 
very mildly ill at the end of the 16 weeks of 
therapy. There was a rise in the mean weight at 
the end of the trial as compared to the basal 
level, with risperidone therapy. 
Extrapyramidal side effects probably pose 
the most important measurable acute problem 
with conventional neuroleptics. Such acute 
symptoms are also important because dystonic 
reactions are certainly alarming to the patients, 
parkinsonian tremor can be embarrassing, and 
akinesia may further complicate schizophrenic 
apathy (Janicak, 1994). Apart from that 
virtually all schizophrenic patients will be on 
indefinite maintenance drug therapy, therefore, 
one must be concerned about adverse events 
that arise with a long term drug exposure. A 
multicentre long term study (Lindstrom et al., 
1995) with risperidone, in Sweden, with 88 
patients observed that treatment of schizo-
phrenic patients with risperidone for 1 and 2 
years was associated with significant reductions 
in positive, negative, excited, and cognitive 
symptoms; a significant amelioration of extrapy-
ramidal symptoms; improved social functioning; 
and a significant reduction in days spent in the 
hospital and thus in treatment costs. For the av-
erage patient, both the avoidance of EPS and 
optimal efficacy appear to occur at doses in the 
2-8 mg range (Davis & Janicak, 1996). The 
much lower incidence of EPS with risperidone, 
compared with haloperidol, has been 
reported (Clauset al., 1992 &'Chouinard etal., 
1993). Patients in risperidone treatment groups 
reported an incidence of adverse side effects 
which was equal to or slightly greater than that 
observed in the placebo group. No treatment 
dependent trends in laboratory, electrocardio-
gram, or vital signs measures were noted, and 
no serious side effects were reported. 
In our study, though, adverse effects were 
reported by 40% of the patients, they were mild. 
No serious side effects reported in any of the 
patients. Even the Extrapyramidal Symptoms 
(EPS) which were seen in some of the patients 
were well controlled either by reducing the dose 
of risperidone or with trihexyphenidyl hydrochlo-
ride tablets administration. There was no 
worsening of the extrapyramidal rating scale 
scores at any of the time in the trial which 
further endorses the safety of the drug. The 
efficacy and safety was further reflected in the 
fact that.the patients who had completed the 
trial as per the protocol for 16 weeks still 
insisted on continuing with the drug and were 
continuing to enjoy the relief of the symptoms. 
There were no significant changes in any of the 
other safety parameters studied during the trial. 
The authors found risperidone to be sig-
nificantly useful in the treatment of schizophre-
nia. Its administration lead to improvement in 
the wide range of symptoms, including the nega-
tive symptoms. 
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